ScholarIQanswers from OpenAlex & ORCID
Stephen Chan
ResearcherPublications, citations & collaboration network
Stephen Chan is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Stephen Chan have?
ScholarIQindexed works
Stephen Chan has 327 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Stephen Chan have?
ScholarIQcitation count
Stephen Chan has 17,327 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Stephen Chan?
ScholarIQh-index
Stephen Chan has an h-index of 60 in OpenAlex.
What is the i10-index of Stephen Chan?
ScholarIQi10-index
Stephen Chan has an i10-index of 145 in OpenAlex.
What is the ORCID of Stephen Chan?
ScholarIQorcid
The ORCID for Stephen Chan is on the source record.
What is the OpenAlex record for Stephen Chan?
ScholarIQopenalex
The OpenAlex for Stephen Chan is on the source record.
What are the most-cited papers on Stephen Chan?
ScholarIQmost cited works
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Adam Brufsky, Igor Bondarenko, Oleg Lipatov, Edith A. Perez, Denise A. Yardley, Stephen Chan, Xian Zhou, S. Phan, Joyce O’Shaughnessy
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt, Holly Tovey, Maggie C.U. Cheang, Sarah Kernaghan, Lucy Kilburn, Patrycja Gazińska, Julie Owen, Jacinta Abraham, Sophie Barrett, Peter Barrett‐Lee, Robert Brown, Stephen Chan, Mitch Dowsett, James M. Flanagan, Lisa Fox, Anita Grigoriadis, Alexander Gutin, Catherine Harper‐Wynne, M. Hatton, Katherine A. Hoadley, Jyoti Parikh, Peter J. Parker, Charles M. Perou, Rebecca Roylance, Vandna Shah, Adam Shaw, Ian E. Smith, Kirsten M. Timms, Andrew Wardley, G. Wilson, Cheryl Gillett, Jerry S. Lanchbury, Alan Ashworth, Nazneen Rahman, Mark Harries, Paul Ellis, Sarah E. Pinder, Judith M. Bliss
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
Stephen Chan, Kay Friedrichs, D. Noel, Tamás Pintér, Simon Van Belle, Daniel Vorobiof, Ricardo Jordão Duarte, Miguel Gil Gil, I. Bodrogi, Elizabeth Murray, Louise Yelle, Gϋnter von Minckwitz, S Korec, Peter Simmonds, Franco Buzzi, Rosario González Mancha, Gary Richardson, Euan Walpole, Monica Ronzoni, M Murawsky, May Alakl, A. Riva, John Crown
Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer
Stephen Chan, M. E. Scheulen, S. Johnston, K. Mross, Fátima Cardoso, Christian Dittrich, W. Eiermann, Dagmar Hess, Rudolph Morant, Semiglazov Vf, Markus Borner, Marc Salzberg, Valerijus Ostapenko, H. J. Illiger, Dirk Behringer, Nathalie Bardy‐Bouxin, Joseph Boni, Steven Kong, Maria Cincotta, Laurence Moore
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid, Jacinta Abraham, Stephen Chan, Duncan Wheatley, Adrian Murray Brunt, Gia Nemsadze, Richard D. Baird, Yeon Hee Park, Peter S Hall, Timothy Perren, Robert C. Stein, László Mangel, Jean-Marc Ferrero, Melissa Phillips, John Conibear, Javier Cortés, Andrew Foxley, Elza C. de Bruin, Robert McEwen, Daniel Stetson, Brian Dougherty, Shah‐Jalal Sarker, Aaron Prendergast, Max McLaughlin-Callan, Matthew Burgess, Cheryl Lawrence, Hayley Cartwright, Kelly Mousa, Nicholas C. Turner